Latest News and Press Releases

Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.

Applied Biologics presents interim CAMPX Trial data at SAWC Spring 2026, highlighting encouraging wound closure trends for XWRAP® in diabetic foot ulcers.

>20 year‑old venous leg ulcers show dramatic healing and pain elimination with revyveThermoreversible revyve transforms deep tunneling wound care, delivering 90% wound volume reductionrevyve...

Merakris’ MTX-001 research wins SAWC award; human data show significant wound healing. Phase 2 ongoing with FDA and manufacturing catalysts ahead.

WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter...

WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert...

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

FRAMINGHAM, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...

FRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...